BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/20/2014 9:09:00 AM | Browse: 1393 | Download: 1937
 |
Received |
|
2014-05-26 17:08 |
|
Peer-Review Started |
|
2014-05-26 17:47 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2014-06-19 10:58 |
|
Revised |
|
2014-07-01 23:34 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2014-09-10 13:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2014-09-10 14:03 |
|
Articles in Press |
|
2014-09-10 14:04 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-10-13 11:59 |
|
Publish the Manuscript Online |
|
2014-10-20 09:08 |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Multimodality management of resectable gastric cancer: A review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Helen Shum and Lakshmi Rajdev |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Lakshmi Rajdev, MD, MS, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Road, 2nd Floor, Bronx, NY 10461, United States. lrajdev@montefiore.org |
| Key Words |
Neoadjuvant chemotherapy; Adjuvant chemotherapy; Adjuvant chemoradiation; Gastric cancer; Gastric adenocarcinoma |
| Core Tip |
Gastric adenocarcinoma is a difficult disease to treat. Surgical resection is the definitive therapy but recurrences are frequent. The use of a multidisciplinary approach to treatment decision-making is imperative. Surgical resection should be an R0 resection (with clear macroscopic and microscopic margins) and at least a D1 lymphadenectomy with a minimum of 15 lymph nodes sampled in the United States and a D2 lymphadenectomy elsewhere. Perioperative chemotherapy is a reasonable option based on the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. In patients who are evaluated after resection, adjuvant chemoradiation adds important survival benefit. Other options include adjuvant S-1 in Asian patients, capecitabine/oxaliplatin, and capecitabine/cisplatin. |
| Publish Date |
2014-10-20 09:08 |
| Citation |
Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol 2014; 6(10): 393-402 |
| URL |
http://www.wjgnet.com/1948-5204/full/v6/i10/393.htm |
| DOI |
http://dx.doi.org/10.4251/wjgo.v6.i10.393 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
